Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>Delta Gold Technologies 31.0p £18.29m (AQSE:DGQ) The technology Company developing intellectual property (IP) in the quantum computing sector announced a Research Sponsorship and exclusive Technology Licensing Agreement with Penn State University in Pennsylvania, USA.</li>
<li>Penn State's recent published work includes structures and methods for quantum computing using gold, which aligns closely with Delta's research at the University of Toronto.</li>
<li>The Agreement forms part of Delta's long-term strategy to build a global centre of excellence and a world-class portfolio in quantum materials research across leading universities. </li>
</ul>


Delta Gold Technologies 31.0p £18.29m (AQSE:DGQ) The technology Company developing intellectual property (IP) in the quantum computing sector announced a Research Sponsorship and exclusive Technology Licensing Agreement with Penn State University in Pennsylvania, USA.
Penn State's recent published work includes structures and methods for quantum computing using gold, which aligns closely with Delta's research at the University of Toronto.
The Agreement forms part of Delta's long-term strategy to build a global centre of excellence and a world-class portfolio in quantum materials research across leading universities. 


Hybridan Small Cap Feast: 12 February 2026

<ul><li>A flow of new contracts have been announced so far in December adding to the evidence of business progress.</li><li>The relatively new biometrics department reported a new client, Global Antibiotic Research & Development Partnership (GARDP).</li><li>This is a not-for-profit research and development organisation that addresses global public health needs by developing new or improved antibiotic treatments, while endeavouring to ensure sustainable access.</li></ul>

A flow of new contracts have been announced so far in December adding to the evidence of business progress.The relatively new biometrics department reported a new client, Global Antibiotic Research & Development Partnership (GARDP).This is a not-for-profit research and development organisation that addresses global public health needs by developing new or improved antibiotic treatments, while endeavouring to ensure sustainable access.

<ul>
<li>Alien Metals 0.125p £11.6m (UFO.L) The minerals exploration and development company has reported that its joint venture partner, West Coast Silver Limited has announced that it has entered into a non-binding Memorandum of Understanding with Artemis Resources Limited to evaluate the potential for Artemis' Radio Hill Processing Plant, located near Karratha, to process material sourced from West Coast's Elizabeth Hill Silver Mine in the Pilbara.</li>
<li>Digitalbox 4.75p £5.6m (DBOX.L) The mobile-first digital media business, with websites such as the Entertainment Daily, The Daily Mash, The Poke, The Tab and TV Guide updates on its Q4 period in 2025.</li>
<li>The Company expects EBITDA for the FY December 2025 to be significantly ahead of expectations while revenue to be broadly in line. </li>
</ul>


Alien Metals 0.125p £11.6m (UFO.L) The minerals exploration and development company has reported that its joint venture partner, West Coast Silver Limited has announced that it has entered into a non-binding Memorandum of Understanding with Artemis Resources Limited to evaluate the potential for Artemis' Radio Hill Processing Plant, located near Karratha, to process material sourced from West Coast's Elizabeth Hill Silver Mine in the Pilbara.
Digitalbox 4.75p £5.6m (DBOX.L) The mobile-first digital media business, with websites such as the Entertainment Daily, The Daily Mash, The Poke, The Tab and TV Guide updates on its Q4 period in 2025.
The Company expects EBITDA for the FY December 2025 to be significantly ahead of expectations while revenue to be broadly in line. 


Hybridan Small Cap Feast: 4 December 2025

<ul>
<li>The high-growth operator with a portfolio of assets across key Colombian hydrocarbon basins reports for the three months ended 31 March 2026.</li>
<li>The average corporate production increased 15.4% to 4,715 boe/d. making $23.5m of total oil and natural gas revenue which is 21% higher than Q1 last year.</li>
<li>The EBITDA is $14.1m, a 22% increase when compared to Q1 2025. </li>
</ul>


The high-growth operator with a portfolio of assets across key Colombian hydrocarbon basins reports for the three months ended 31 March 2026.
The average corporate production increased 15.4% to 4,715 boe/d. making $23.5m of total oil and natural gas revenue which is 21% higher than Q1 last year.
The EBITDA is $14.1m, a 22% increase when compared to Q1 2025. 


<ul>
<li>Autins Group 13p £7.1m (AUTG.L) The UK and European-based manufacturer of its proprietary Neptune melt-blown material and specialist in acoustic and thermal insulation solutions, provided an update on its financing arrangements.</li>
<li>Further to the Group's recent trading update, Autins confirms that it has now repaid the remaining £0.75m balance of its existing loan facility with Maven Capital Partners that was originally entered into in 2020.</li>
<li>The Group has also entered into a new £1.0m 4 year term loan facility, also with Maven via MEIF II. </li>
</ul>


Autins Group 13p £7.1m (AUTG.L) The UK and European-based manufacturer of its proprietary Neptune melt-blown material and specialist in acoustic and thermal insulation solutions, provided an update on its financing arrangements.
Further to the Group's recent trading update, Autins confirms that it has now repaid the remaining £0.75m balance of its existing loan facility with Maven Capital Partners that was originally entered into in 2020.
The Group has also entered into a new £1.0m 4 year term loan facility, also with Maven via MEIF II. 


United Kingdom

Physiomics is a data-driven consultancy that provides Model-Informed Drug Development (MIDD), Biostatistics, Statistical Programming, and Bioinformatics solutions to biopharmaceutical companies and research institutes. The company utilizes its proprietary Virtual Tumour technology platform to optimize the design of cancer clinical trials and predict the effects of treatments. Physiomics was founded in 2001 and is headquartered in Abingdon, United Kingdom.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Physiomics (PYC LN)

Hybridan Small Cap Feast: 12 February 2026

Penn State's recent published work includes structures and methods for quantum computing using gold, which aligns closely with Delta's research at...

Hybridan

Hybridan Research: Physiomics plc

A flow of new contracts have been announced so far in December adding to the evidence of business progress. The relatively new biometrics...

Hybridan

Hybridan Small Cap Feast: 4 December 2025

The Company expects EBITDA for the FY December 2025 to be significantly ahead of expectations while revenue to be broadly in line.

Hybridan

Hybridan Small Cap Feast: 27 May 2026

The high-growth operator with a portfolio of assets across key Colombian hydrocarbon basins reports for the three months ended 31 March 2026.

Hybridan

Hybridan Small Cap Feast: 12 May 2026

he UK and European-based manufacturer of its proprietary Neptune melt-blown material and specialist in acoustic and thermal insulation solutions...

Hybridan

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)